NFE2L2 and persistent truncus arteriosus: It is worth mentioning that the administration of ML385, a specific inhibitor of Nrf2, markedly attenuated the protective effects of PTA on cardiac systolic dysfunction induced by TAC, when compared with the TAC + PTA group.